Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis

* Patient must voluntarily sign and date a patient authorization. * Patient must be ≥ 18 years of age. * Patient must have confirmed diagnosis of UC. * Patient must have: 1. a Mayo endoscopic sub score of 2 or 3 from endoscopic investigation in the previous 3-months that is closest to the baseline visit or 2. a Mayo rectal bleeding subscore ≥ 2 and a calprotectin value greater than 250 µg/gr. * Patient must have been prescribed adalimumab as part of his treatment by his treating physician. * If the patient was previously treated with vedolizumab or any anti-TNF agent (except adalimumab), an appropriate washout has taken place as per routine practice.

* Patient has previously received adalimumab. * Patient has previously used infliximab or any anti-TNF agent and have not clinically responded at any time ("primary non-responder") unless they experienced a treatment limiting reaction. * Patient with a history of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for UC or planned bowel surgery. * Patient with a current diagnosis of indeterminate colitis, ulcerative proctitis only, or with a current diagnosis and/or have a history of Crohn's disease. * Patient with other tumor necrosis factor (TNF) immune-modulated disease. * Patient has a significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, cardiovascular, or hepatic disease that in the opinion of the investigator would adversely affect his/her participating in this study. * A female patient is pregnant or breast-feeding. * Patient is currently participating in another prospective study including controlled clinical trials and observational studies